chr7:116672196:> Detail (hg38) (MET)

Information

Genome

Assembly Position
hg19 chr7:116,312,250-116,438,431 
hg38 chr7:116,672,196-116,798,377

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
Score Disease name Description Source Pubmed Links
<0.001 Adenocarcinoma, Scirrhous NA BeFree Detail
0.129 squamous cell carcinoma MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of... BeFree,CTD_human,LHGDN 25492085 Detail
<0.001 Carcinoma, Transitional Cell NA BeFree Detail
0.002 Neoplastic Cell Transformation NA GAD Detail
<0.001 chondrosarcoma NA BeFree Detail
0.001 chordoma We find that miR-34a inversely correlates with MET expression and miR-608 invers... BeFree 24621885 Detail
0.120 Cognition Disorders NA CTD_human Detail
<0.001 ulcerative colitis NA BeFree Detail
0.003 Colonic Neoplasms NA LHGDN Detail
0.008 colorectal carcinoma The presented data subclassified CRCs based on their activated signaling pathway... BeFree 25090459 Detail
0.008 colorectal carcinoma Disruption of the DATE increased HGF signaling via MET and reduced levels of rec... BeFree 25244939 Detail
0.008 colorectal carcinoma Consistently, we found that, in human colorectal cancer tissues, high levels of ... BeFree 25306394 Detail
0.008 colorectal carcinoma Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulati... BeFree 25381815 Detail
0.008 colorectal carcinoma Moreover, the data suggested that the combination of c-Met-targeted therapy with... BeFree 25427200 Detail
0.008 colorectal carcinoma ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Surviva... BeFree 26026086 Detail
0.020 Colorectal Neoplasms NA BeFree,LHGDN Detail
0.003 cystic fibrosis NA BeFree Detail
0.080 Diabetes Mellitus, Experimental NA RGD Detail
0.003 Pathological accumulation of air in tissues NA LHGDN Detail
0.083 Endometrial Neoplasms NA BeFree,LHGDN,RGD Detail
<0.001 endometriosis NA BeFree Detail
0.120 Esophageal Neoplasms NA BeFree,CTD_human Detail
0.003 Fatty Liver NA LHGDN Detail
<0.001 fibrosarcoma NA BeFree Detail
<0.001 gastrinoma NA BeFree Detail
<0.001 Giant Cell Tumors NA BeFree Detail
0.129 glioblastoma Clinically, patients afflicted with ZM fusion harboring glioblastomas survived p... BeFree,CTD_human,LHGDN 25135958 Detail
0.129 glioblastoma Our data provide new insights into the potential application of miR-144-3p in GB... BeFree,CTD_human,LHGDN 26250785 Detail
0.129 glioblastoma Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targ... BeFree,CTD_human,LHGDN 26381735 Detail
0.087 Glioma Our study profiles the shifting RNA landscape of gliomas during progression and ... BeFree,LHGDN,RGD 25135958 Detail
0.087 Glioma Interestingly, the expression of MET was up-regulated and inversely associated w... BeFree,LHGDN,RGD 26250785 Detail
0.080 Cardiomegaly NA RGD Detail
0.002 Atrial Septal Defects Incomplete penetrance in this family was consistent with MET as a partial suscep... BeFree 24909855 Detail
<0.001 hepatitis B NA BeFree Detail
0.080 Hepatitis, Animal NA RGD Detail
0.120 Hepatitis, Chronic NA CTD_human Detail
<0.001 hepatitis C NA BeFree Detail
<0.001 Von Hippel-Lindau syndrome NA BeFree Detail
<0.001 Hodgkin Disease NA BeFree Detail
0.002 Hyperparathyroidism, Secondary NA GAD Detail
<0.001 Immunologic Deficiency Syndromes NA BeFree Detail
<0.001 Kidney Failure, Chronic NA BeFree Detail
0.001 Kidney Neoplasm NA BeFree Detail
<0.001 leukemia NA BeFree Detail
<0.001 chronic lymphocytic leukemia We evaluated the expression of c-MET on nurse-like cells and monocytes from pati... BeFree 24561793 Detail
0.121 Leukemia, Myelocytic, Acute NA BeFree,CTD_human Detail
<0.001 Leukemia, T-Cell NA BeFree Detail
0.003 Adult T-Cell Lymphoma/Leukemia NA BeFree,LHGDN Detail
<0.001 liver cirrhosis NA BeFree Detail
0.080 Liver Cirrhosis, Experimental NA RGD Detail
0.084 Liver neoplasms NA BeFree,LHGDN,RGD Detail
0.120 Liver Neoplasms, Experimental NA CTD_human Detail
0.002 Chronic Obstructive Airway Disease NA GAD Detail
0.138 Lung Neoplasms NA BeFree,CTD_human,LHGDN Detail
0.003 lymphedema NA LHGDN Detail
0.004 lymphoma NA BeFree,LHGDN Detail
0.012 Malignant neoplasm of stomach HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a ... BeFree 25157953 Detail
0.012 Malignant neoplasm of stomach Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregio... BeFree 25203738 Detail
0.012 Malignant neoplasm of stomach Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-M... BeFree 25248999 Detail
0.012 Malignant neoplasm of stomach Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridizati... BeFree 25364819 Detail
0.012 Malignant neoplasm of stomach In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosi... BeFree 25395073 Detail
0.012 Malignant neoplasm of stomach Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-depende... BeFree 25504634 Detail
0.012 Malignant neoplasm of stomach The prevalence of genomic copy number aberrations of epidermal growth factor rec... BeFree 25558650 Detail
0.012 Malignant neoplasm of stomach In this study, we demonstrated that several receptor tyrosine kinase (RTK), incl... BeFree 25576915 Detail
0.012 Malignant neoplasm of stomach Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour ... BeFree 25584489 Detail
0.012 Malignant neoplasm of stomach Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer meta... BeFree 25653235 Detail
0.012 Malignant neoplasm of stomach Approximately 10 - 20% of gastric cancer presented an increased MET gene copy nu... BeFree 25881479 Detail
0.012 Malignant neoplasm of stomach c-Met targeting in advanced gastric cancer: An open challenge. BeFree 26049023 Detail
0.012 Malignant neoplasm of stomach We also showed that HOTAIR recruiting and binding to PRC2 epigenetically repress... BeFree 26136075 Detail
<0.001 Marijuana Abuse NA BeFree Detail
0.002 medulloblastoma Coagulation pathway sensors (F3/TF, F2R/PAR-1) are expressed in MB in a subtype-... BeFree 25163932 Detail
0.002 medulloblastoma Here, we report that the analysis of several large nonoverlapping cohorts of pat... BeFree 25391241 Detail
0.004 melanoma PAX3 and ETS1 synergistically activate MET expression in melanoma cells. BeFree 25531327 Detail
0.004 melanoma Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway... BeFree 25910030 Detail
<0.001 Melanosis NA BeFree Detail
0.001 Mesothelioma NA BeFree Detail
0.003 Metaplasia NA LHGDN Detail
<0.001 Microphthalmos NA BeFree Detail
<0.001 Monoclonal Gammopathy of Undetermined Significance NA BeFree Detail
<0.001 Mucocutaneous Lymph Node Syndrome NA BeFree Detail
0.005 multiple myeloma NA BeFree,LHGDN Detail
0.002 multiple sclerosis NA GAD Detail
<0.001 myocardial infarction NA BeFree Detail
0.003 myopia NA BeFree,GAD Detail
0.003 Nasal Polyps NA BeFree,GAD Detail
0.120 Neoplasm Invasiveness NA CTD_human Detail
0.150 Neoplasm Metastasis While EMT/MET has long been recognized as an essential component of early embryo... BeFree,CTD_human,LHGDN 24447705 Detail
0.150 Neoplasm Metastasis Expression of CAIX, PI3K p110a, and c-MET in metastases did not predict objectiv... BeFree,CTD_human,LHGDN 24980447 Detail
0.150 Neoplasm Metastasis MET amplification was associated with adenocarcinomas (P = 0.007), high-grade tu... BeFree,CTD_human,LHGDN 25326232 Detail
0.150 Neoplasm Metastasis High MET mRNA expression (score ≥3) was associated with lymph node metastasis (P... BeFree,CTD_human,LHGDN 25364819 Detail
0.150 Neoplasm Metastasis Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulati... BeFree,CTD_human,LHGDN 25381815 Detail
0.150 Neoplasm Metastasis MET mutational analyses were performed in tumors, adjacent normal tissues as wel... BeFree,CTD_human,LHGDN 25416047 Detail
0.150 Neoplasm Metastasis MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by ta... BeFree,CTD_human,LHGDN 25611392 Detail
0.150 Neoplasm Metastasis Further studies indicated that the HGF/MET signaling pathway was involved in in ... BeFree,CTD_human,LHGDN 25640943 Detail
0.150 Neoplasm Metastasis Based on the metastasis-related mRNA microarray analysis and subsequent western ... BeFree,CTD_human,LHGDN 25845387 Detail
0.003 nephritis NA LHGDN Detail
0.120 neuroblastoma NA CTD_human Detail
<0.001 acoustic neuroma NA BeFree Detail
<0.001 Adenoma of large intestine Using a large sigmoidoscopy-based case-control study (753 cases and 799 controls... BeFree 15767338 Detail
<0.001 oligodendroglioma NA BeFree Detail
0.003 Oropharyngeal Neoplasms NA LHGDN Detail
<0.001 Degenerative polyarthritis NA BeFree Detail
0.128 osteosarcoma NA BeFree,CTD_human,LHGDN Detail
0.003 ovarian carcinoma While EMT/MET has long been recognized as an essential component of early embryo... BeFree 24447705 Detail
0.003 ovarian carcinoma Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for pe... BeFree 25209149 Detail
0.085 Pancreatic Neoplasm NA BeFree,GAD,LHGDN,RGD Detail
0.080 pancreatitis NA RGD Detail
<0.001 Paresis NA BeFree Detail
<0.001 pericardial effusion Using patient-derived tumor cell models isolated from pericardial effusion of HE... BeFree 25157953 Detail
0.080 periodontitis NA RGD Detail
<0.001 Pleural effusion disorder MET was the most highly overexpressed gene in malignant pleural mesothelioma com... BeFree 25756049 Detail
<0.001 polycythemia vera NA BeFree Detail
<0.001 Adenomatous Polyposis Coli NA BeFree Detail
<0.001 Precancerous Conditions NA BeFree Detail
0.011 Prostatic Neoplasms NA BeFree,LHGDN Detail
<0.001 Psychotic Disorders NA BeFree Detail
0.003 purpura NA LHGDN Detail
0.002 Refractive Errors NA GAD Detail
<0.001 kidney failure NA BeFree Detail
0.080 Reperfusion Injury NA RGD Detail
<0.001 Rett syndrome NA BeFree Detail
0.007 rhabdomyosarcoma NA BeFree,LHGDN Detail
0.002 rhinitis NA GAD Detail
0.123 schizophrenia NA BeFree,CTD_human,GAD Detail
0.003 systemic scleroderma NA BeFree,LHGDN Detail
0.122 sinusitis NA CTD_human,GAD Detail
0.003 Skin Ulcer NA LHGDN Detail
0.124 Stomach Neoplasms In two MET-amplified human gastric tumor xenograft models, SNU-5 and Hs 746T, in... BeFree,CTD_human,LHGDN 25504634 Detail
<0.001 gastric ulcer NA BeFree Detail
<0.001 substance dependence Increase of MET gene copy number confers resistance to a monovalent MET antibody... BeFree 25011627 Detail
<0.001 synovial sarcoma NA BeFree Detail
<0.001 thymoma Furthermore, we show that ectopically expressed SPINT2 in melanoma cells inhibit... BeFree 25910030 Detail
0.003 Thyroid Neoplasm NA BeFree,LHGDN Detail
0.080 Gilles de la Tourette syndrome NA MGD Detail
<0.001 Trisomy NA BeFree Detail
<0.001 Unipolar Depression NA BeFree Detail
<0.001 xeroderma pigmentosum NA BeFree Detail
<0.001 Zollinger-Ellison syndrome NA BeFree Detail
<0.001 diffuse large B-cell lymphoma NA BeFree Detail
<0.001 T-Cell Lymphoma NA BeFree Detail
<0.001 severe combined immunodeficiency NA BeFree Detail
<0.001 Liver failure NA BeFree Detail
<0.001 benign neoplasm NA BeFree Detail
<0.001 Squamous cell carcinoma of lung Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic sig... BeFree 25522678 Detail
<0.001 renal fibrosis NA BeFree Detail
<0.001 Muscle Weakness NA BeFree Detail
0.003 Adenocarcinoma of lung (disorder) Data were reviewed for patients with advanced lung adenocarcinomas enrolled in t... BeFree 25273224 Detail
0.003 Adenocarcinoma of lung (disorder) Consecutive lung adenocarcinoma specimens (n = 176) 'double-negative' (wild-type... BeFree 25344360 Detail
0.003 Adenocarcinoma of lung (disorder) MET FISH-positive status predicts short progression-free survival and overall su... BeFree 25886066 Detail
<0.001 esophageal carcinoma NA BeFree Detail
<0.001 Malignant neoplasm of nasopharynx NA BeFree Detail
<0.001 Secondary malignant neoplasm of lung NA BeFree Detail
0.001 Secondary malignant neoplasm of bone Matriptase and MET are prominently expressed at the site of bone metastasis in r... BeFree 25186085 Detail
0.080 Liver Failure, Acute NA BeFree,RGD Detail
<0.001 Mitochondrial Myopathies NA BeFree Detail
0.008 Tumor Progression Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treate... BeFree 25087088 Detail
0.008 Tumor Progression Mounting studies highlighted the essential role of the HGF/c-MET axis in driving... BeFree 25607934 Detail
0.008 Tumor Progression The MET and RON receptors are tyrosine kinases that form a non-covalent complex ... BeFree 25874493 Detail
<0.001 Anaplastic carcinoma NA BeFree Detail
<0.001 Liposarcoma, Dedifferentiated The hepatocyte growth factor receptor as a potential therapeutic target for dedi... BeFree 26006023 Detail
<0.001 Neuroectodermal Tumors NA BeFree Detail
<0.001 Liposarcoma, Myxoid NA BeFree Detail
<0.001 Sarcoma, Clear Cell NA BeFree Detail
<0.001 leiomyomatosis NA BeFree Detail
<0.001 alveolar rhabdomyosarcoma NA BeFree Detail
<0.001 alveolar soft part sarcoma NA BeFree Detail
0.001 Adenocarcinoma, Clear Cell NA BeFree Detail
<0.001 adrenocortical carcinoma MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear ce... BeFree 25087088 Detail
0.086 cholangiocarcinoma NA BeFree,LHGDN,RGD Detail
<0.001 Carcinoma, Large Cell NA BeFree Detail
<0.001 Cervical Intraepithelial Neoplasia NA BeFree Detail
<0.001 Neuroendocrine Tumors NA BeFree Detail
<0.001 uveal melanoma NA BeFree Detail
<0.001 Malignant neoplasm of salivary gland NA BeFree Detail
<0.001 Carcinoma of unknown primary NA BeFree Detail
<0.001 Metastatic malignant neoplasm to brain NA BeFree Detail
<0.001 Melanosis coli NA BeFree Detail
<0.001 Emotional disorder There have been several reports on the association between the Val(158)Met genet... BeFree 23748501 Detail
<0.001 Renal Cell Dysplasia NA BeFree Detail
0.002 pancreatic carcinoma The roles of these proteins as markers for stemness in pancreatic cancer as well... BeFree 24925031 Detail
<0.001 Gastrointestinal Stromal Tumors Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal St... BeFree 25836719 Detail
<0.001 Cancer of Nasopharynx NA BeFree Detail
<0.001 Anaplastic thyroid carcinoma NA BeFree Detail
<0.001 Medullary carcinoma of thyroid NA BeFree Detail
0.002 Papillary thyroid carcinoma NA BeFree Detail
<0.001 Defect of diaphragm This search revealed putatively deleterious sequence changes in four other genes... BeFree 25736269 Detail
0.023 Malignant neoplasm of lung Data were reviewed for patients with advanced lung adenocarcinomas enrolled in t... BeFree,GAD 25273224 Detail
0.023 Malignant neoplasm of lung In this study, using the prostate cancer cell line PC3 and the non-small lung ca... BeFree,GAD 25449774 Detail
0.023 Malignant neoplasm of lung Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whe... BeFree,GAD 25492085 Detail
0.023 Malignant neoplasm of lung SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibit... BeFree,GAD 25656847 Detail
0.023 Malignant neoplasm of lung Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors... BeFree,GAD 25777467 Detail
<0.001 Multiple tumors NA BeFree Detail
<0.001 Malignant neoplasm of stomach stage IV NA BeFree Detail
<0.001 Metastatic osteosarcoma NA BeFree Detail
<0.001 gastric adenocarcinoma Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients w... BeFree 24626858 Detail
0.003 Cancer of Head and Neck Silk-elastinlike protein polymer (SELP) hydrogels were used for matrix-mediated ... BeFree,GAD 24962819 Detail
<0.001 Liver and Intrahepatic Biliary Tract Carcinoma NA BeFree Detail
<0.001 Squamous cell carcinoma of esophagus The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and la... BeFree 25884729 Detail
0.001 Adenocarcinoma Of Esophagus NA BeFree Detail
<0.001 Conventional (Clear Cell) Renal Cell Carcinoma NA BeFree Detail
0.002 Solid tumour Silk-elastinlike protein polymer (SELP) hydrogels were used for matrix-mediated ... BeFree 24962819 Detail
0.002 Solid tumour MET amplification was detected in 2.6% of patients with solid tumors and was ass... BeFree 25326232 Detail
0.002 Solid tumour Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors... BeFree 25777467 Detail
<0.001 stage, prostate cancer These findings establish the importance of MET in prostate cancer progression bu... BeFree 25381262 Detail
<0.001 Squamous cell carcinoma of oropharynx NA BeFree Detail
<0.001 Squamous cell carcinoma of tonsil NA BeFree Detail
<0.001 desmoplastic small round cell tumor Novel somatic mutations were identified in four out of 18 patients with advanced... BeFree 25119929 Detail
<0.001 Adenomatous goiter NA BeFree Detail
<0.001 Healing ulcer NA BeFree Detail
<0.001 anaplastic astrocytoma Interestingly, the ZM fusion was found only in grade III astrocytomas (1/13; 7.7... BeFree 25135958 Detail
<0.001 Epiretinal Membrane NA BeFree Detail
<0.001 Malignant neoplasm of liver NA BeFree Detail
<0.001 malignant mesothelioma NA BeFree Detail
<0.001 Multiple malignancy NA BeFree Detail
0.002 Malignant neoplasm of pancreas The roles of these proteins as markers for stemness in pancreatic cancer as well... BeFree 24925031 Detail
<0.001 Nonorganic psychosis NA BeFree Detail
<0.001 Malignant lymphoma of testis NA BeFree Detail
<0.001 Arrhythmogenic Right Ventricular Dysplasia Gene‐elusive patients who had done the most intense (top quartile MET‐Hrs/year) ... BeFree 25516436 Detail
0.004 Malignant neoplasm of prostate MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear ce... BeFree 25087088 Detail
0.004 Malignant neoplasm of prostate These findings establish the importance of MET in prostate cancer progression bu... BeFree 25381262 Detail
0.004 Malignant neoplasm of prostate In this study, using the prostate cancer cell line PC3 and the non-small lung ca... BeFree 25449774 Detail
<0.001 Impaired exercise tolerance NA BeFree Detail
<0.001 endometrial carcinoma NA BeFree Detail
0.002 Secondary malignant neoplasm of liver NA BeFree Detail
<0.001 Malignant neoplasm of esophagus NA BeFree Detail
0.001 Thyroid carcinoma NA BeFree Detail
<0.001 Ewings sarcoma Novel somatic mutations were identified in four out of 18 patients with advanced... BeFree 25119929 Detail
0.002 Squamous cell carcinoma of skin NA GAD Detail
<0.001 Malignant glioma NA BeFree Detail
0.002 Osteosarcoma of bone NA BeFree Detail
0.011 Carcinogenesis NA BeFree Detail
<0.001 Tumor Initiation Activation of the MET/HGF pathway is common in human cancer and is thought to pr... BeFree 25504634 Detail
0.004 prostate carcinoma MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear ce... BeFree 25087088 Detail
0.004 prostate carcinoma These findings establish the importance of MET in prostate cancer progression bu... BeFree 25381262 Detail
0.004 prostate carcinoma In this study, using the prostate cancer cell line PC3 and the non-small lung ca... BeFree 25449774 Detail
<0.001 toxic shock syndrome NA BeFree Detail
0.001 Epithelial ovarian cancer NA BeFree Detail
<0.001 invasive cancer NA BeFree Detail
<0.001 Refractory cancer NA BeFree Detail
0.011 Carcinoma of lung Data were reviewed for patients with advanced lung adenocarcinomas enrolled in t... BeFree 25273224 Detail
0.011 Carcinoma of lung In this study, using the prostate cancer cell line PC3 and the non-small lung ca... BeFree 25449774 Detail
0.011 Carcinoma of lung Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whe... BeFree 25492085 Detail
0.011 Carcinoma of lung SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibit... BeFree 25656847 Detail
0.011 Carcinoma of lung Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors... BeFree 25777467 Detail
0.002 Secondary malignant neoplasm of lymph node High MET mRNA expression (score ≥3) was associated with lymph node metastasis (P... BeFree 25364819 Detail
<0.001 Cancer Relapse NA BeFree Detail
0.003 colon carcinoma NA BeFree Detail
0.015 stomach carcinoma HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a ... BeFree 25157953 Detail
0.015 stomach carcinoma Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregio... BeFree 25203738 Detail
0.015 stomach carcinoma Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-M... BeFree 25248999 Detail
0.015 stomach carcinoma Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridizati... BeFree 25364819 Detail
0.015 stomach carcinoma In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosi... BeFree 25395073 Detail
0.015 stomach carcinoma Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-depende... BeFree 25504634 Detail
0.015 stomach carcinoma The prevalence of genomic copy number aberrations of epidermal growth factor rec... BeFree 25558650 Detail
0.015 stomach carcinoma In this study, we demonstrated that several receptor tyrosine kinase (RTK), incl... BeFree 25576915 Detail
0.015 stomach carcinoma Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour ... BeFree 25584489 Detail
0.015 stomach carcinoma Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer meta... BeFree 25653235 Detail
0.015 stomach carcinoma Approximately 10 - 20% of gastric cancer presented an increased MET gene copy nu... BeFree 25881479 Detail
0.015 stomach carcinoma c-Met targeting in advanced gastric cancer: An open challenge. BeFree 26049023 Detail
0.015 stomach carcinoma We also showed that HOTAIR recruiting and binding to PRC2 epigenetically repress... BeFree 26136075 Detail
0.015 stomach carcinoma Mechanistically, miR-449c may target MET to suppress GC cell growth. BeFree 26141986 Detail
<0.001 Carcinoma of bladder NA BeFree Detail
0.003 Malignant neoplasm of kidney NA BeFree Detail
<0.001 Poorly differentiated carcinoma NA BeFree Detail
<0.001 Well Differentiated Oligodendroglioma NA BeFree Detail
<0.001 Malignant Squamous Cell Neoplasm NA BeFree Detail
<0.001 malignant peripheral nerve sheath tumor NA BeFree Detail
0.002 malignant pleural mesothelioma EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in hu... BeFree 25028262 Detail
0.002 malignant pleural mesothelioma MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant p... BeFree 25221930 Detail
0.002 malignant pleural mesothelioma MET was the most highly overexpressed gene in malignant pleural mesothelioma com... BeFree 25756049 Detail
0.001 Rhabdoid Tumor of the Kidney NA BeFree Detail
<0.001 Adenocarcinoma of lung, stage I NA BeFree Detail
0.005 Hereditary Papillary Renal Carcinoma NA BeFree Detail
0.123 ovarian neoplasm NA CTD_human,LHGDN Detail
<0.001 Ovarian adenocarcinoma NA BeFree Detail
<0.001 Colorectal cancer metastatic NA BeFree Detail
<0.001 Gastrooesophageal cancer NA BeFree Detail
0.002 Malignant neoplasm of ovary While EMT/MET has long been recognized as an essential component of early embryo... BeFree 24447705 Detail
0.002 Malignant neoplasm of ovary Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for pe... BeFree 25209149 Detail
<0.001 High-Grade Prostatic Intraepithelial Neoplasia NA BeFree Detail
0.002 Squamous cell carcinoma of the head and neck All nine HNSCC cell lines showed a varying degree of MET protein and RNA express... BeFree 26504020 Detail
0.004 sarcoma NA BeFree,LHGDN Detail
<0.001 major depressive disorder NA BeFree Detail
<0.001 Inflammatory disorder Our work identifies an unprecedented role of MET in neutrophils, suggests a pote... BeFree 25985180 Detail
<0.001 Primary Effusion Lymphoma NA BeFree Detail
<0.001 Adenoma of large intestine NA BeFree Detail
<0.001 Congenital naevus NA BeFree Detail
0.001 papillary renal cell carcinoma NA BeFree Detail
<0.001 Congenital melanocytic nevus NA BeFree Detail
<0.001 Hereditary Malignant Neoplasm NA BeFree Detail
<0.001 Invasive Carcinoma NA BeFree Detail
<0.001 Metastatic Malignant Peripheral Nerve Sheath Tumor NA BeFree Detail
<0.001 pancreatic ductal adenocarcinoma NA BeFree Detail
0.120 Type 1 Papillary Renal Cell Carcinoma NA UNIPROT Detail
<0.001 differentiated thyroid gland carcinoma NA BeFree Detail
<0.001 Epithelioma NA BeFree Detail
0.003 renal carcinoma NA BeFree Detail
0.009 Mammary Neoplasms NA BeFree,LHGDN Detail
<0.001 drug dependence Increase of MET gene copy number confers resistance to a monovalent MET antibody... BeFree 25011627 Detail
0.002 Autism Spectrum Disorders A familial heterozygous null mutation of MET in autism spectrum disorder. BeFree 24909855 Detail
<0.001 Hepatocarcinogenesis NA BeFree Detail
<0.001 Cancer Cell Growth Inhibition of FGFR3 increased target cell apoptosis through the suppression of B... BeFree 24662823 Detail
<0.001 ovarian clear cell adenocarcinoma NA BeFree Detail
<0.001 Secondary Glioblastoma RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript ... BeFree 25135958 Detail
0.001 Tumor Angiogenesis NA BeFree Detail
<0.001 Xenograft Model Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-M... BeFree 25248999 Detail
<0.001 Xenograft Model We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an ex... BeFree 25522765 Detail
0.008 colorectal cancer The presented data subclassified CRCs based on their activated signaling pathway... BeFree 25090459 Detail
0.008 colorectal cancer Disruption of the DATE increased HGF signaling via MET and reduced levels of rec... BeFree 25244939 Detail
0.008 colorectal cancer Consistently, we found that, in human colorectal cancer tissues, high levels of ... BeFree 25306394 Detail
0.008 colorectal cancer Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulati... BeFree 25381815 Detail
0.008 colorectal cancer Moreover, the data suggested that the combination of c-Met-targeted therapy with... BeFree 25427200 Detail
0.008 colorectal cancer ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Surviva... BeFree 26026086 Detail
<0.001 Non-Malignant Ascites Adverse Event NA BeFree Detail
<0.001 Glioblastoma multiforme In cells and tumors that express EGFRvIII, SHP2 also antagonizes the phosphoryla... BeFree 24951116 Detail
<0.001 Glioblastoma multiforme Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM sp... BeFree 25374033 Detail
<0.001 Cirrhosis NA BeFree Detail
<0.001 Benign Prostatic Hyperplasia NA BeFree Detail
<0.001 Non-Neoplastic Disorder NA BeFree Detail
<0.001 Mammographic Density NA BeFree Detail
<0.001 INTELLIGENCE QUANTITATIVE TRAIT LOCUS 1 NA BeFree Detail
0.120 Copper-Overload Cirrhosis NA CTD_human Detail
<0.001 uterine corpus cancer NA BeFree Detail
0.003 plasma cell neoplasm NA LHGDN Detail
0.003 Precursor Cell Lymphoblastic Leukemia Lymphoma NA LHGDN Detail
0.080 Autism, susceptibility to, 9 NA MGD Detail
<0.001 Urothelial Carcinoma NA BeFree Detail
0.340 liver carcinoma We examined the expression of MACC1 and its target genes MET and FAK by quantita... BeFree,CTD_human,LHGDN,RGD,UNIPROT 24516351 Detail
0.340 liver carcinoma Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated wi... BeFree,CTD_human,LHGDN,RGD,UNIPROT 24992910 Detail
0.340 liver carcinoma Mounting studies highlighted the essential role of the HGF/c-MET axis in driving... BeFree,CTD_human,LHGDN,RGD,UNIPROT 25607934 Detail
0.340 liver carcinoma MET is a predictive factor for late recurrence but not for overall survival of e... BeFree,CTD_human,LHGDN,RGD,UNIPROT 25874493 Detail
<0.001 hereditary renal cell carcinoma NA BeFree Detail
0.080 Acute kidney injury NA RGD Detail
<0.001 Familial renal cell carcinoma NA BeFree Detail
0.001 Nasopharyngeal carcinoma MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by ta... BeFree 25611392 Detail
0.120 Papillary renal cell carcinoma, familial NA ORPHANET Detail
<0.001 Proliferative Inflammatory Atrophy NA BeFree Detail
<0.001 Renal dysplasia NA BeFree Detail
<0.001 Triple Negative Breast Neoplasms Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative bre... BeFree 24970481 Detail
<0.001 Fibromyxosarcoma NA BeFree Detail
<0.001 Acidosis, Lactic NA BeFree Detail
0.147 adenocarcinoma MET amplification was detected in 2.6% of patients with solid tumors and was ass... BeFree,CTD_human,LHGDN 25326232 Detail
0.147 adenocarcinoma Importantly, MET amplifications occur at equal frequencies in squamous and adeno... BeFree,CTD_human,LHGDN 25492085 Detail
0.147 adenocarcinoma With that in view, we examined the correlations between MET gene status as asses... BeFree,CTD_human,LHGDN 25886066 Detail
0.006 adenoma NA BeFree,LHGDN Detail
0.003 amyotrophic lateral sclerosis NA BeFree,LHGDN Detail
<0.001 rheumatoid arthritis NA BeFree Detail
<0.001 Astrocytoma NA BeFree Detail
0.141 autistic disorder Implication of MET in normal and pathological brain development opens new perspe... BeFree,CTD_human,GAD,LHGDN 24909855 Detail
0.003 Malignant neoplasm of urinary bladder NA BeFree,GAD Detail
<0.001 bladder neck obstruction NA BeFree Detail
<0.001 Bladder Neoplasm NA BeFree Detail
<0.001 Bone neoplasms NA BeFree Detail
0.001 Brain Neoplasms Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. BeFree 24748276 Detail
<0.001 Burkitt lymphoma NA BeFree Detail
0.003 Malignant tumor of colon NA BeFree Detail
<0.001 Malignant neoplasm of endometrium NA BeFree Detail
<0.001 Malignant neoplasm of thyroid NA BeFree Detail
<0.001 Bronchioloalveolar Adenocarcinoma NA BeFree Detail
0.003 Noninfiltrating Intraductal Carcinoma NA LHGDN Detail
0.141 Non-small cell lung carcinoma MET and ALK as targets for the treatment of NSCLC. BeFree,CTD_human 24138716 Detail
0.141 Non-small cell lung carcinoma Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib... BeFree,CTD_human 24687921 Detail
0.141 Non-small cell lung carcinoma Similar to EGFR mutations, ALK rearrangements exemplify an oncogene-driven NSCLC... BeFree,CTD_human 24857124 Detail
0.141 Non-small cell lung carcinoma Prevalence of MET positivity by IHC was higher in non-squamous cell NSCLC, MET o... BeFree,CTD_human 25039923 Detail
0.141 Non-small cell lung carcinoma Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitor... BeFree,CTD_human 25052479 Detail
0.141 Non-small cell lung carcinoma Increased NQO1 but not c-MET and survivin expression in non-small cell lung carc... BeFree,CTD_human 25222473 Detail
0.141 Non-small cell lung carcinoma Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell... BeFree,CTD_human 25226813 Detail
0.141 Non-small cell lung carcinoma MET gene copy number predicts worse overall survival in patients with non-small ... BeFree,CTD_human 25232729 Detail
0.141 Non-small cell lung carcinoma Unfortunately, acquired drug resistance emerges in these patients due to the amp... BeFree,CTD_human 25310337 Detail
0.141 Non-small cell lung carcinoma The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbo... BeFree,CTD_human 25322323 Detail
0.141 Non-small cell lung carcinoma Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET ... BeFree,CTD_human 25413260 Detail
0.141 Non-small cell lung carcinoma MET amplification is not a mutually exclusive genetic event in therapy-naïve non... BeFree,CTD_human 25492085 Detail
0.141 Non-small cell lung carcinoma Activated MET acts as a salvage signal after treatment with alectinib, a selecti... BeFree,CTD_human 25502629 Detail
0.141 Non-small cell lung carcinoma Expression of the oncogene hepatocyte growth factor receptor (MET) and phosphory... BeFree,CTD_human 25522678 Detail
0.141 Non-small cell lung carcinoma We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an ex... BeFree,CTD_human 25522765 Detail
0.141 Non-small cell lung carcinoma The mesenchymal-epithelial transition (MET) protein is the only known receptor f... BeFree,CTD_human 25532429 Detail
0.141 Non-small cell lung carcinoma Addition of the EGFR inhibitor gefitinib restores the sensitivity of SMARCE1-kno... BeFree,CTD_human 25656847 Detail
0.141 Non-small cell lung carcinoma A partial response was observed in a patient with MET immunohistochemistry 3+ NS... BeFree,CTD_human 25777467 Detail
0.141 Non-small cell lung carcinoma Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating ... BeFree,CTD_human 25831463 Detail
0.141 Non-small cell lung carcinoma MET: a new promising biomarker in non-small-cell lung carcinoma. BeFree,CTD_human 25893986 Detail
0.141 Non-small cell lung carcinoma Therefore, targeting γ-catenin-mediated HAI-1 expression might be a useful strat... BeFree,CTD_human 25925948 Detail
0.004 Carcinoma, Papillary NA BeFree,LHGDN Detail
0.253 renal cell carcinoma If these results are further validated in a similar population, they could be in... BeFree,CLINVAR,CTD_human,LHGDN 24767687 Detail
0.253 renal cell carcinoma MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear ce... BeFree,CLINVAR,CTD_human,LHGDN 25087088 Detail
0.253 renal cell carcinoma Matriptase and MET are prominently expressed at the site of bone metastasis in r... BeFree,CLINVAR,CTD_human,LHGDN 25186085 Detail
Annotation

Annotations

DescrptionSourceLinks
NA DisGeNET Detail
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We find that miR-34a inversely correlates with MET expression and miR-608 inversely correlates with ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The presented data subclassified CRCs based on their activated signaling pathways and identify a rol... DisGeNET Detail
Disruption of the DATE increased HGF signaling via MET and reduced levels of receptor-interacting se... DisGeNET Detail
Consistently, we found that, in human colorectal cancer tissues, high levels of TNF-α correlates wit... DisGeNET Detail
Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling... DisGeNET Detail
Moreover, the data suggested that the combination of c-Met-targeted therapy with chemotherapy or irr... DisGeNET Detail
ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Canc... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Clinically, patients afflicted with ZM fusion harboring glioblastomas survived poorly relative to th... DisGeNET Detail
Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeti... DisGeNET Detail
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glio... DisGeNET Detail
Our study profiles the shifting RNA landscape of gliomas during progression and reveled ZM as a nove... DisGeNET Detail
Interestingly, the expression of MET was up-regulated and inversely associated with miR-144-3p level... DisGeNET Detail
NA DisGeNET Detail
Incomplete penetrance in this family was consistent with MET as a partial susceptibility gene for AS... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We evaluated the expression of c-MET on nurse-like cells and monocytes from patients with chronic ly... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of p... DisGeNET Detail
Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer p... DisGeNET Detail
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and gro... DisGeNET Detail
Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinic... DisGeNET Detail
In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosis and inhibited down... DisGeNET Detail
Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression ... DisGeNET Detail
The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human ... DisGeNET Detail
In this study, we demonstrated that several receptor tyrosine kinase (RTK), including EGFR, HER3 and... DisGeNET Detail
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. DisGeNET Detail
Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. DisGeNET Detail
Approximately 10 - 20% of gastric cancer presented an increased MET gene copy numbers; inappropriate... DisGeNET Detail
c-Met targeting in advanced gastric cancer: An open challenge. DisGeNET Detail
We also showed that HOTAIR recruiting and binding to PRC2 epigenetically represses miR34a, which con... DisGeNET Detail
NA DisGeNET Detail
Coagulation pathway sensors (F3/TF, F2R/PAR-1) are expressed in MB in a subtype-specific manner, and... DisGeNET Detail
Here, we report that the analysis of several large nonoverlapping cohorts of patients with medullobl... DisGeNET Detail
PAX3 and ETS1 synergistically activate MET expression in melanoma cells. DisGeNET Detail
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melan... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
While EMT/MET has long been recognized as an essential component of early embryonic development, the... DisGeNET Detail
Expression of CAIX, PI3K p110a, and c-MET in metastases did not predict objective response. DisGeNET Detail
MET amplification was associated with adenocarcinomas (P = 0.007), high-grade tumors (P = 0.003), mo... DisGeNET Detail
High MET mRNA expression (score ≥3) was associated with lymph node metastasis (P = .014), distant me... DisGeNET Detail
Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling... DisGeNET Detail
MET mutational analyses were performed in tumors, adjacent normal tissues as well as in lymph nodes ... DisGeNET Detail
MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. DisGeNET Detail
Further studies indicated that the HGF/MET signaling pathway was involved in in vitro motility and i... DisGeNET Detail
Based on the metastasis-related mRNA microarray analysis and subsequent western blotting confirmatio... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Using a large sigmoidoscopy-based case-control study (753 cases and 799 controls) in Los Angeles Cou... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
While EMT/MET has long been recognized as an essential component of early embryonic development, the... DisGeNET Detail
Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of the... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Using patient-derived tumor cell models isolated from pericardial effusion of HER2(+) and MET(+) GC ... DisGeNET Detail
NA DisGeNET Detail
MET was the most highly overexpressed gene in malignant pleural mesothelioma compared to benign asbe... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
In two MET-amplified human gastric tumor xenograft models, SNU-5 and Hs 746T, intravenous treatment ... DisGeNET Detail
NA DisGeNET Detail
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes dru... DisGeNET Detail
NA DisGeNET Detail
Furthermore, we show that ectopically expressed SPINT2 in melanoma cells inhibits the HGF-induced ME... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squam... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutat... DisGeNET Detail
Consecutive lung adenocarcinoma specimens (n = 176) 'double-negative' (wild-type EGFR and KRAS) were... DisGeNET Detail
MET FISH-positive status predicts short progression-free survival and overall survival after gefitin... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma:... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treated patients with no r... DisGeNET Detail
Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progressi... DisGeNET Detail
The MET and RON receptors are tyrosine kinases that form a non-covalent complex on the cell surface ... DisGeNET Detail
NA DisGeNET Detail
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposar... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
There have been several reports on the association between the Val(158)Met genetic polymorphism of t... DisGeNET Detail
NA DisGeNET Detail
The roles of these proteins as markers for stemness in pancreatic cancer as well as recent studies w... DisGeNET Detail
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
This search revealed putatively deleterious sequence changes in four other genes that have been show... DisGeNET Detail
Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutat... DisGeNET Detail
In this study, using the prostate cancer cell line PC3 and the non-small lung cancer cell line A549,... DisGeNET Detail
Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whereas 3% show a clear... DisGeNET Detail
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. DisGeNET Detail
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lu... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocar... DisGeNET Detail
Silk-elastinlike protein polymer (SELP) hydrogels were used for matrix-mediated delivery of oncolyti... DisGeNET Detail
NA DisGeNET Detail
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance o... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Silk-elastinlike protein polymer (SELP) hydrogels were used for matrix-mediated delivery of oncolyti... DisGeNET Detail
MET amplification was detected in 2.6% of patients with solid tumors and was associated with adenoca... DisGeNET Detail
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lu... DisGeNET Detail
These findings establish the importance of MET in prostate cancer progression but reveal potential l... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Novel somatic mutations were identified in four out of 18 patients with advanced ES and two of 10 pa... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Interestingly, the ZM fusion was found only in grade III astrocytomas (1/13; 7.7%) or secondary GBMs... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
The roles of these proteins as markers for stemness in pancreatic cancer as well as recent studies w... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Gene‐elusive patients who had done the most intense (top quartile MET‐Hrs/year) exercise prior to pr... DisGeNET Detail
MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial... DisGeNET Detail
These findings establish the importance of MET in prostate cancer progression but reveal potential l... DisGeNET Detail
In this study, using the prostate cancer cell line PC3 and the non-small lung cancer cell line A549,... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Novel somatic mutations were identified in four out of 18 patients with advanced ES and two of 10 pa... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Activation of the MET/HGF pathway is common in human cancer and is thought to promote tumor initiati... DisGeNET Detail
MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial... DisGeNET Detail
These findings establish the importance of MET in prostate cancer progression but reveal potential l... DisGeNET Detail
In this study, using the prostate cancer cell line PC3 and the non-small lung cancer cell line A549,... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutat... DisGeNET Detail
In this study, using the prostate cancer cell line PC3 and the non-small lung cancer cell line A549,... DisGeNET Detail
Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whereas 3% show a clear... DisGeNET Detail
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. DisGeNET Detail
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lu... DisGeNET Detail
High MET mRNA expression (score ≥3) was associated with lymph node metastasis (P = .014), distant me... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of p... DisGeNET Detail
Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer p... DisGeNET Detail
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and gro... DisGeNET Detail
Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinic... DisGeNET Detail
In conclusion, knockdown of the c‑Met gene promoted gastric cancer cell apoptosis and inhibited down... DisGeNET Detail
Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression ... DisGeNET Detail
The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human ... DisGeNET Detail
In this study, we demonstrated that several receptor tyrosine kinase (RTK), including EGFR, HER3 and... DisGeNET Detail
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. DisGeNET Detail
Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. DisGeNET Detail
Approximately 10 - 20% of gastric cancer presented an increased MET gene copy numbers; inappropriate... DisGeNET Detail
c-Met targeting in advanced gastric cancer: An open challenge. DisGeNET Detail
We also showed that HOTAIR recruiting and binding to PRC2 epigenetically represses miR34a, which con... DisGeNET Detail
Mechanistically, miR-449c may target MET to suppress GC cell growth. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleura... DisGeNET Detail
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. DisGeNET Detail
MET was the most highly overexpressed gene in malignant pleural mesothelioma compared to benign asbe... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
While EMT/MET has long been recognized as an essential component of early embryonic development, the... DisGeNET Detail
Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of the... DisGeNET Detail
NA DisGeNET Detail
All nine HNSCC cell lines showed a varying degree of MET protein and RNA expression. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Our work identifies an unprecedented role of MET in neutrophils, suggests a potential 'Achilles' hee... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes dru... DisGeNET Detail
A familial heterozygous null mutation of MET in autism spectrum disorder. DisGeNET Detail
NA DisGeNET Detail
Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, fo... DisGeNET Detail
NA DisGeNET Detail
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary gliobla... DisGeNET Detail
NA DisGeNET Detail
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and gro... DisGeNET Detail
We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EG... DisGeNET Detail
The presented data subclassified CRCs based on their activated signaling pathways and identify a rol... DisGeNET Detail
Disruption of the DATE increased HGF signaling via MET and reduced levels of receptor-interacting se... DisGeNET Detail
Consistently, we found that, in human colorectal cancer tissues, high levels of TNF-α correlates wit... DisGeNET Detail
Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling... DisGeNET Detail
Moreover, the data suggested that the combination of c-Met-targeted therapy with chemotherapy or irr... DisGeNET Detail
ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Canc... DisGeNET Detail
NA DisGeNET Detail
In cells and tumors that express EGFRvIII, SHP2 also antagonizes the phosphorylation of EGFRvIII and... DisGeNET Detail
Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM spheres by 30-50% with... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
We examined the expression of MACC1 and its target genes MET and FAK by quantitative PCR in 160 pati... DisGeNET Detail
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis vi... DisGeNET Detail
Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progressi... DisGeNET Detail
MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocel... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
MET amplification was detected in 2.6% of patients with solid tumors and was associated with adenoca... DisGeNET Detail
Importantly, MET amplifications occur at equal frequencies in squamous and adenocarcinomas without o... DisGeNET Detail
With that in view, we examined the correlations between MET gene status as assessed by fluorescence ... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Implication of MET in normal and pathological brain development opens new perspectives for understan... DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
NA DisGeNET Detail
MET and ALK as targets for the treatment of NSCLC. DisGeNET Detail
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in adva... DisGeNET Detail
Similar to EGFR mutations, ALK rearrangements exemplify an oncogene-driven NSCLC that can be effecti... DisGeNET Detail
Prevalence of MET positivity by IHC was higher in non-squamous cell NSCLC, MET or EGFR amplified cas... DisGeNET Detail
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell ... DisGeNET Detail
Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS muta... DisGeNET Detail
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell li... DisGeNET Detail
MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NS... DisGeNET Detail
Unfortunately, acquired drug resistance emerges in these patients due to the amplification of the Me... DisGeNET Detail
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rea... DisGeNET Detail
Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently ... DisGeNET Detail
MET amplification is not a mutually exclusive genetic event in therapy-naïve non-small cell lung can... DisGeNET Detail
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in... DisGeNET Detail
Expression of the oncogene hepatocyte growth factor receptor (MET) and phosphorylation of the MET pr... DisGeNET Detail
We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EG... DisGeNET Detail
The mesenchymal-epithelial transition (MET) protein is the only known receptor for hepatocyte growth... DisGeNET Detail
Addition of the EGFR inhibitor gefitinib restores the sensitivity of SMARCE1-knockdown cells to MET ... DisGeNET Detail
A partial response was observed in a patient with MET immunohistochemistry 3+ NSCLC without MET gene... DisGeNET Detail
Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathway... DisGeNET Detail
MET: a new promising biomarker in non-small-cell lung carcinoma. DisGeNET Detail
Therefore, targeting γ-catenin-mediated HAI-1 expression might be a useful strategy to sensitize NSC... DisGeNET Detail
NA DisGeNET Detail
If these results are further validated in a similar population, they could be incorporated into futu... DisGeNET Detail
MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial... DisGeNET Detail
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma:... DisGeNET Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
dbSNP
rs386493716 dbSNP
Genome
hg38
Position
chr7:116,672,196-116,798,377
Variant Type
snv
Variant (CIViC) (CIViC Variant)
EXON 14 MUTATION
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/2778
Genome browser